Nuclear receptors: Emerging drug targets for parasitic diseases

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Parasitic worms infect billions of people worldwide. Current treatments rely on a small group of drugs that have been used for decades. A shortcoming of these drugs is their inability to target the intractable infectious stage of the parasite. As wellknown therapeutic targets in mammals, nuclear receptors have begun to be studied in parasitic worms, where they are widely distributed and play key roles in governing metabolic and developmental transcriptional networks. One such nuclear receptor is DAF-12, which is required for normal nematode development, including the all-important infectious stage. Here we review the emerging literature that implicates DAF-12 and potentially other nuclear receptors as novel anthelmintic targets.

Original languageEnglish (US)
Pages (from-to)1165-1171
Number of pages7
JournalJournal of Clinical Investigation
Issue number4
StatePublished - Apr 3 2017

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Nuclear receptors: Emerging drug targets for parasitic diseases'. Together they form a unique fingerprint.

Cite this